Purvalanol A (CDK Inhibitor) Global Market Report 2025
상품코드:1855961
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
Purvalanol A(CDK 억제제) 시장 규모는 최근 급속히 확대되고 있습니다. 2024년 5억 8,000만 달러로 평가되었고, 2025년에는 6억 4,000만 달러에 달하고, CAGR 10.1%로 성장할 전망입니다. 실적기간의 성장은 암 유병률 증가, 암 연구에 대한 자금 제공 증가, 표적 치료에 대한 수요 증가, CDK 억제의 채택률의 상승, 맞춤형 의료에 대한 의식 증가에 기인하고 있습니다.
Purvalanol A(CDK 억제제) 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 9.7%로 9억 2,000만 달러로 성장할 전망입니다. 예측기간에서 성장의 원동력은 노인 인구 증가, 만성질환의 이환율 증가, 생명공학의 기술 혁신의 성장, 연구등급 화합물의 가용성 확대, 학계와 제약기업 간의 협력관계의 확대입니다. 예측기간의 주요 동향으로는 선택적 CDK 억제의 발전, 차세대 Purvalanol 유도체의 개발, 표적암 치료의 혁신, 세포투과성 억제제 제제의 진보, 병용 치료 전략의 성장 등이 있습니다.
암의 유병률 상승이 Purvalanol A(CDK 억제제) 시장의 성장을 가속할 것으로 예측되고 있습니다. 암은 인근 조직이나 기관에 침입할 수 있는 비정상 세포의 무질서한 발생과 확산에 의해 특징지어지는 상태입니다. 이러한 유병률 증가는 주로 유전자 변이와 만성 염증의 위험을 높이는 생활 습관 관련 요인 때문입니다. 사이클린 의존성 키나아제 억제제인 Purvalanol A는 세포주기의 제어에 관여하는 주요 효소를 표적으로 함으로써 암세포의 성장과 증식을 억제하고 암에 대처하는 역할을 합니다. 예를 들어 2024년 4월 영국을 거점으로 하는 자선단체 맥밀란 캔서 지원은 이 나라에서 암과 함께 사는 사람의 수가 2025년까지 350만명, 2030년까지 400만명, 2040년까지 500만명을 돌파할 것으로 예측하고 있다고 보고했습니다. 따라서 암 환자수 증가가 Purvalanol A(CDK 억제제) 시장의 확대에 기여하고 있습니다.
헬스케어 지출 증가는 Purvalanol A(CDK 억제제) 시장의 성장을 지원할 것으로 예측됩니다. 헬스케어 지출이란 치료, 기기, 인프라, 노동력 등 의료서비스에 할당되는 재원의 총액을 가리키며, 공공 부문과 민간부문 모두 이에 해당합니다. 이 지출은 종종 장기적이고 자원 집약적인 관리가 필요한 만성 질환의 부담 증가로 인해 증가하는 경향이 있습니다. 예를 들어 2024년 5월 영국 정부 기관인 국가 통계국은 2022년부터 2023년까지 총 의료비가 명목 기준으로 5.6% 증가한다고 보고했습니다. 그 결과, 헬스케어 투자 증가가 Purvalanol A(CDK 억제제) 시장의 발전에 기여하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 Purvalanol A(CDK 억제제) : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 Purvalanol A(CDK 억제제) 시장 : 성장률 분석
세계의 Purvalanol A(CDK 억제제) 시장 실적 : 규모와 성장, 2019년-2024년
세계의 Purvalanol A(CDK 억제제) 시장 예측 : 규모와 성장, 2024년-2029년, 2034년
세계의 Purvalanol A(CDK 억제제) : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 Purvalanol A(CDK 억제제) 시장 : 유형별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
CDK1 억제
CDK2 억제
CDK4 억제
CDK6 억제
듀얼 CDK 억제
세계의 Purvalanol A(CDK 억제제) 시장 : 용도별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
암 치료
심혈관 질환
자가면역질환
신경질환
감염증
세계의 Purvalanol A(CDK 억제제) 시장 : 최종 사용자별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
제약기업
연구기관
바이오테크놀러지 기업
병원
진단 실험실
세계의 Purvalanol A(CDK 억제제) 시장 : 세분화 CDK1 저해, 유형별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
ATP 경쟁 억제제
비ATP 경쟁 억제제
알로스테릭 억제제
세계의 Purvalanol A(CDK 억제제) 시장 : 세분화 CDK2 저해, 유형별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
선택적 CDK2 억제제
범 CDK 억제
펩티드계 억제제
세계의 Purvalanol A(CDK 억제제) 시장 : 세분화 CDK4 저해, 유형별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
저분자 억제제
단일클론항체
병용 요법 억제제
세계의 Purvalanol A(CDK 억제제) 시장 : 세분화 CDK6 저해, 유형별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
ATP 경쟁 억제제
선택적 CDK6 억제제
듀얼 CDK4/6 억제제
세계의 Purvalanol A(CDK 억제제) 시장 : 세분화 듀얼 CDK 저해, 유형별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
CDK1/2 듀얼 억제제
CDK4/6 듀얼 억제제
멀티 CDK 억제
제7장 지역별/국가별 분석
세계의 Purvalanol A(CDK 억제제) 시장 : 지역별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
세계의 Purvalanol A(CDK 억제제) 시장 : 국가별, 분석과 예측, 2019년-2024년, 2024년-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
Purvalanol A(CDK 억제제) 시장 : 경쟁 구도
Purvalanol A(CDK 억제제) 시장 : 기업 프로파일
Merck Kommanditgesellschaft auf Aktien : 개요, 제품 및 서비스, 전략 및 재무 분석
Bio-Techne Corporation : 개요, 제품 및 서비스, 전략 및 재무 분석
Cayman Chemical Company Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Selleck Chemicals LLC : 개요, 제품 및 서비스, 전략 및 재무 분석
Santa Cruz Biotechnology Inc : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
TargetMol Chemicals Inc.
MedChemExpress LLC
DC Chemicals Co. Ltd.
BOC Sciences
AdooQ BioScience LLC
Focus Biomolecules LLC
APExBIO Technology LLC
LKT Laboratories Inc.
Medkoo Biosciences Inc.
Alomone Labs Ltd.
Glentham Life Sciences Ltd.
Global Life Sciences Solutions LLC
AdipoGen Life Sciences
Enzo Biochem Inc.
Zibo Hangyu Biotechnology Development Co. Ltd.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
Purvalanol A(CDK 억제제) 시장 2029년 : 새로운 기회를 제공하는 국가
Purvalanol A(CDK 억제제) 시장 2029년 : 새로운 기회를 제공하는 부문
Purvalanol A(CDK 억제제) 시장 2029년 : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
SHW
영문 목차
영문목차
Purvalanol A is a potent and selective small-molecule cyclin-dependent kinase (CDK) inhibitor that targets CDK1, CDK2, CDK4, and CDK5, disrupting cell cycle progression. It is primarily used in cancer research to study cell cycle regulation, apoptosis, and potential therapeutic strategies for tumor suppression.
The primary types of Purvalanol A (CDK inhibitor) include CDK1 inhibition, CDK2 inhibition, CDK4 inhibition, CDK6 inhibition, and dual CDK inhibition. CDK1 inhibition involves targeted suppression of cyclin-dependent kinase 1 activity, which is crucial for regulating cell cycle progression and controlling the proliferation of diseased or cancerous cells. Purvalanol A is applied in cancer treatment, cardiovascular diseases, autoimmune diseases, neurological disorders, and infectious diseases. Key end-users include pharmaceutical companies, research institutions, biotechnology firms, hospitals, and diagnostic laboratories.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The purvalanol A (CDK inhibitor) market research report is one of a series of new reports from The Business Research Company that provides purvalanol A (CDK inhibitor) market statistics, including the purvalanol A (CDK inhibitor) industry global market size, regional shares, competitors with the purvalanol A (CDK inhibitor) market share, detailed purvalanol A (CDK inhibitor) market segments, market trends, and opportunities, and any further data you may need to thrive in the purvalanol A (CDK inhibitor) industry. This purvalanol A (CDK inhibitor) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The purvalanol A (CDK inhibitor) market size has grown rapidly in recent years. It will grow from $0.58 billion in 2024 to $0.64 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period is attributed to the increasing prevalence of cancer, rising funding for cancer research, growing demand for targeted therapies, higher adoption of CDK inhibitors, and increasing awareness of personalized medicine.
The purvalanol A (CDK inhibitor) market size is expected to see strong growth in the next few years. It will grow to $0.92 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period is driven by a rising geriatric population, increasing incidence of chronic diseases, growth in biotechnology innovations, greater availability of research-grade compounds, and expanding collaborations between academia and pharmaceutical companies. Key trends in the forecast period include advancements in selective CDK inhibitors, development of next-generation Purvalanol derivatives, innovation in targeted cancer therapies, progress in cell-permeable inhibitor formulations, and growth in combination treatment strategies.
The rising prevalence of cancer is expected to drive growth in the purvalanol A (CDK inhibitor) market. Cancer is a condition marked by the uncontrolled development and spread of abnormal cells that may invade nearby tissues and organs. This increasing prevalence is primarily due to lifestyle-related factors that elevate the risk of genetic mutations and chronic inflammation. Purvalanol A, a cyclin-dependent kinase inhibitor, plays a role in addressing cancer by targeting key enzymes involved in cell cycle regulation, helping to reduce cancer cell growth and proliferation. For example, in April 2024, Macmillan Cancer Support, a charity based in the United Kingdom, reported that the number of individuals living with cancer in the country is projected to surpass three and a half million by 2025, four million by 2030, and five point three million by 2040. Therefore, the growing number of cancer cases is contributing to the expansion of the purvalanol A (CDK inhibitor) market.
The increasing level of healthcare expenditure is expected to support growth in the purvalanol A (CDK inhibitor) market. Healthcare expenditure refers to the total financial resources allocated for medical services, including treatments, equipment, infrastructure, and workforce, by both public and private sectors. This spending is on the rise due to the growing burden of chronic diseases, which often require long-term, resource-intensive management. Greater investment in healthcare enables funding for research, clinical development, and broader availability of targeted therapies such as purvalanol A. For instance, in May 2024, the Office for National Statistics, a government department in the United Kingdom, reported a five point six percent increase in total healthcare expenditure in nominal terms from 2022 to 2023, a notable rise compared to the zero point nine percent growth observed the previous year. As a result, increased healthcare investment is contributing to the advancement of the purvalanol A (CDK inhibitor) market.
In December 2023, Danaher Corporation, a science and technology company based in the United States, acquired Abcam plc for an undisclosed sum. Through this acquisition, Danaher aims to incorporate Abcam's broad portfolio of high-quality antibodies and research reagents into its life sciences and diagnostics offerings, thereby strengthening its capabilities to support scientific discovery. Abcam plc is a company based in the United Kingdom that provides purvalanol A.
Major players in the purvalanol a (cdk inhibitor) market are Merck Kommanditgesellschaft auf Aktien, Bio-Techne Corporation, Cayman Chemical Company Inc., Selleck Chemicals LLC, Santa Cruz Biotechnology Inc, TargetMol Chemicals Inc. , MedChemExpress LLC, DC Chemicals Co. Ltd., BOC Sciences, AdooQ BioScience LLC, Focus Biomolecules LLC, APExBIO Technology LLC, LKT Laboratories Inc., Medkoo Biosciences Inc. , Alomone Labs Ltd., Glentham Life Sciences Ltd., Global Life Sciences Solutions LLC, AdipoGen Life Sciences, Enzo Biochem Inc., Zibo Hangyu Biotechnology Development Co. Ltd.
North America was the largest region in the purvalanol A (CDK inhibitor) market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in purvalanol A (CDK Inhibitor) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the purvalanol A (CDK Inhibitor) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The purvalanol A (CDK Inhibitor) market consists of sales of products such as research-grade purvalanol A, cell-permeable CDK inhibitors, purvalanol A derivatives, high-purity chemical compounds for preclinical studies, and combination therapy formulations. Values in this market are 'factory gate' values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Purvalanol A (CDK Inhibitor) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on purvalanol a (cdk inhibitor) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for purvalanol a (cdk inhibitor) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The purvalanol a (cdk inhibitor) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Purvalanol A (CDK Inhibitor) Market Characteristics
3. Purvalanol A (CDK Inhibitor) Market Trends And Strategies
4. Purvalanol A (CDK Inhibitor) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Purvalanol A (CDK Inhibitor) Growth Analysis And Strategic Analysis Framework
5.1. Global Purvalanol A (CDK Inhibitor) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Purvalanol A (CDK Inhibitor) Market Growth Rate Analysis
5.4. Global Purvalanol A (CDK Inhibitor) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Purvalanol A (CDK Inhibitor) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Purvalanol A (CDK Inhibitor) Total Addressable Market (TAM)
6. Purvalanol A (CDK Inhibitor) Market Segmentation
6.1. Global Purvalanol A (CDK Inhibitor) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
CDK1 Inhibition
CDK2 Inhibition
CDK4 Inhibition
CDK6 Inhibition
Dual CDK Inhibition
6.2. Global Purvalanol A (CDK Inhibitor) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cancer Treatment
Cardiovascular Diseases
Autoimmune Diseases
Neurological Disorders
Infectious Diseases
6.3. Global Purvalanol A (CDK Inhibitor) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pharmaceutical Companies
Research Institutions
Biotechnology Firms
Hospitals
Diagnostic Laboratories
6.4. Global Purvalanol A (CDK Inhibitor) Market, Sub-Segmentation Of CDK1 Inhibition, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
ATP-Competitive Inhibitors
Non-ATP-Competitive Inhibitors
Allosteric Inhibitors
6.5. Global Purvalanol A (CDK Inhibitor) Market, Sub-Segmentation Of CDK2 Inhibition, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Selective CDK2 Inhibitors
Pan-CDK Inhibitors
Peptide-Based Inhibitors
6.6. Global Purvalanol A (CDK Inhibitor) Market, Sub-Segmentation Of CDK4 Inhibition, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Small Molecule Inhibitors
Monoclonal Antibodies
Combination Therapy Inhibitors
6.7. Global Purvalanol A (CDK Inhibitor) Market, Sub-Segmentation Of CDK6 Inhibition, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
ATP-Competitive Inhibitors
Selective CDK6 Inhibitors
Dual CDK4/6 Inhibitors
6.8. Global Purvalanol A (CDK Inhibitor) Market, Sub-Segmentation Of Dual CDK Inhibition, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
CDK1/2 Dual Inhibitors
CDK4/6 dual Inhibitors
Multi-CDK Inhibitors
7. Purvalanol A (CDK Inhibitor) Market Regional And Country Analysis
7.1. Global Purvalanol A (CDK Inhibitor) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Purvalanol A (CDK Inhibitor) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Purvalanol A (CDK Inhibitor) Market
8.1. Asia-Pacific Purvalanol A (CDK Inhibitor) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Purvalanol A (CDK Inhibitor) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Purvalanol A (CDK Inhibitor) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Purvalanol A (CDK Inhibitor) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Purvalanol A (CDK Inhibitor) Market
9.1. China Purvalanol A (CDK Inhibitor) Market Overview
9.2. China Purvalanol A (CDK Inhibitor) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Purvalanol A (CDK Inhibitor) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Purvalanol A (CDK Inhibitor) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Purvalanol A (CDK Inhibitor) Market
10.1. India Purvalanol A (CDK Inhibitor) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Purvalanol A (CDK Inhibitor) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Purvalanol A (CDK Inhibitor) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Purvalanol A (CDK Inhibitor) Market
11.1. Japan Purvalanol A (CDK Inhibitor) Market Overview
11.2. Japan Purvalanol A (CDK Inhibitor) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Purvalanol A (CDK Inhibitor) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Purvalanol A (CDK Inhibitor) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Purvalanol A (CDK Inhibitor) Market
12.1. Australia Purvalanol A (CDK Inhibitor) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Purvalanol A (CDK Inhibitor) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Purvalanol A (CDK Inhibitor) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Purvalanol A (CDK Inhibitor) Market
13.1. Indonesia Purvalanol A (CDK Inhibitor) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Purvalanol A (CDK Inhibitor) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Purvalanol A (CDK Inhibitor) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Purvalanol A (CDK Inhibitor) Market
14.1. South Korea Purvalanol A (CDK Inhibitor) Market Overview
14.2. South Korea Purvalanol A (CDK Inhibitor) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Purvalanol A (CDK Inhibitor) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Purvalanol A (CDK Inhibitor) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Purvalanol A (CDK Inhibitor) Market
15.1. Western Europe Purvalanol A (CDK Inhibitor) Market Overview
15.2. Western Europe Purvalanol A (CDK Inhibitor) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Purvalanol A (CDK Inhibitor) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Purvalanol A (CDK Inhibitor) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Purvalanol A (CDK Inhibitor) Market
16.1. UK Purvalanol A (CDK Inhibitor) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Purvalanol A (CDK Inhibitor) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Purvalanol A (CDK Inhibitor) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Purvalanol A (CDK Inhibitor) Market
17.1. Germany Purvalanol A (CDK Inhibitor) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Purvalanol A (CDK Inhibitor) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Purvalanol A (CDK Inhibitor) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Purvalanol A (CDK Inhibitor) Market
18.1. France Purvalanol A (CDK Inhibitor) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Purvalanol A (CDK Inhibitor) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Purvalanol A (CDK Inhibitor) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Purvalanol A (CDK Inhibitor) Market
19.1. Italy Purvalanol A (CDK Inhibitor) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Purvalanol A (CDK Inhibitor) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Purvalanol A (CDK Inhibitor) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Purvalanol A (CDK Inhibitor) Market
20.1. Spain Purvalanol A (CDK Inhibitor) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Purvalanol A (CDK Inhibitor) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Purvalanol A (CDK Inhibitor) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Purvalanol A (CDK Inhibitor) Market
21.1. Eastern Europe Purvalanol A (CDK Inhibitor) Market Overview
21.2. Eastern Europe Purvalanol A (CDK Inhibitor) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Purvalanol A (CDK Inhibitor) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Purvalanol A (CDK Inhibitor) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Purvalanol A (CDK Inhibitor) Market
22.1. Russia Purvalanol A (CDK Inhibitor) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Purvalanol A (CDK Inhibitor) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Purvalanol A (CDK Inhibitor) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Purvalanol A (CDK Inhibitor) Market
23.1. North America Purvalanol A (CDK Inhibitor) Market Overview
23.2. North America Purvalanol A (CDK Inhibitor) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Purvalanol A (CDK Inhibitor) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Purvalanol A (CDK Inhibitor) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Purvalanol A (CDK Inhibitor) Market
24.1. USA Purvalanol A (CDK Inhibitor) Market Overview
24.2. USA Purvalanol A (CDK Inhibitor) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Purvalanol A (CDK Inhibitor) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Purvalanol A (CDK Inhibitor) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Purvalanol A (CDK Inhibitor) Market
25.1. Canada Purvalanol A (CDK Inhibitor) Market Overview
25.2. Canada Purvalanol A (CDK Inhibitor) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Purvalanol A (CDK Inhibitor) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Purvalanol A (CDK Inhibitor) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Purvalanol A (CDK Inhibitor) Market
26.1. South America Purvalanol A (CDK Inhibitor) Market Overview
26.2. South America Purvalanol A (CDK Inhibitor) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Purvalanol A (CDK Inhibitor) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Purvalanol A (CDK Inhibitor) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Purvalanol A (CDK Inhibitor) Market
27.1. Brazil Purvalanol A (CDK Inhibitor) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Purvalanol A (CDK Inhibitor) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Purvalanol A (CDK Inhibitor) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Purvalanol A (CDK Inhibitor) Market
28.1. Middle East Purvalanol A (CDK Inhibitor) Market Overview
28.2. Middle East Purvalanol A (CDK Inhibitor) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Purvalanol A (CDK Inhibitor) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Purvalanol A (CDK Inhibitor) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Purvalanol A (CDK Inhibitor) Market
29.1. Africa Purvalanol A (CDK Inhibitor) Market Overview
29.2. Africa Purvalanol A (CDK Inhibitor) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Purvalanol A (CDK Inhibitor) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Purvalanol A (CDK Inhibitor) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Purvalanol A (CDK Inhibitor) Market Competitive Landscape And Company Profiles
30.1. Purvalanol A (CDK Inhibitor) Market Competitive Landscape
30.2. Purvalanol A (CDK Inhibitor) Market Company Profiles
30.2.1. Merck Kommanditgesellschaft auf Aktien Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Bio-Techne Corporation Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Cayman Chemical Company Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Selleck Chemicals LLC Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Santa Cruz Biotechnology Inc Overview, Products and Services, Strategy and Financial Analysis
31. Purvalanol A (CDK Inhibitor) Market Other Major And Innovative Companies
31.1. TargetMol Chemicals Inc.
31.2. MedChemExpress LLC
31.3. DC Chemicals Co. Ltd.
31.4. BOC Sciences
31.5. AdooQ BioScience LLC
31.6. Focus Biomolecules LLC
31.7. APExBIO Technology LLC
31.8. LKT Laboratories Inc.
31.9. Medkoo Biosciences Inc.
31.10. Alomone Labs Ltd.
31.11. Glentham Life Sciences Ltd.
31.12. Global Life Sciences Solutions LLC
31.13. AdipoGen Life Sciences
31.14. Enzo Biochem Inc.
31.15. Zibo Hangyu Biotechnology Development Co. Ltd.
32. Global Purvalanol A (CDK Inhibitor) Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Purvalanol A (CDK Inhibitor) Market
34. Recent Developments In The Purvalanol A (CDK Inhibitor) Market
35. Purvalanol A (CDK Inhibitor) Market High Potential Countries, Segments and Strategies
35.1 Purvalanol A (CDK Inhibitor) Market In 2029 - Countries Offering Most New Opportunities
35.2 Purvalanol A (CDK Inhibitor) Market In 2029 - Segments Offering Most New Opportunities
35.3 Purvalanol A (CDK Inhibitor) Market In 2029 - Growth Strategies
